Rafferty Asset Management, LLC Gritstone Bio, Inc. Transaction History

Rafferty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$2.13 - $3.74 $74,875 - $131,472	-35,153 Reduced 59.8%	23,628 $65,000
Q4 2022 Feb 13, 2023	SELL	$2.17 - $3.92 $6,631 - $11,979	-3,056 Reduced 4.94%	58,781 $202,000
Q3 2022 Nov 14, 2022	BUY	$2.46 - $4.75 $30,504 - $58,900	12,400 Added 25.08%	61,837 $159,000
Q2 2022 Aug 12, 2022	SELL	$1.77 - $4.34 $264,806 - $649,298	-149,608 Reduced 75.16%	49,437 $120,000
Q1 2022 May 13, 2022	SELL	$4.03 - $12.19 $1.09 Million - $3.29 Million	-270,194 Reduced 57.58%	199,045 $820,000
Q4 2021 Feb 10, 2022	BUY	$8.76 - $13.71 $4.11 Million - $6.43 Million	469,239 New	469,239 $6.03 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.